Core Insights - BioPorto A/S is sponsoring conferences focused on pediatric solid organ transplants and critical care nephrology, presenting new NGAL scientific data that enhances the identification and management of Acute Kidney Injury (AKI) in patients [1][2]. Group 1: Conference Participation - The International Pediatric Transplant Association (IPTA) held a biennial event in Berlin with over 500 participants, addressing AKI concerns in pediatric patients through various sessions [2]. - Dr. Kyle Merrill and Dr. June Oh presented a special session on NGAL usage, attended by over 100 participants, highlighting its application in patient cases [2]. - The 5th International Symposium on AKI in Children commenced on September 26 in Cincinnati, aiming for scientific collaboration across pediatric communities [2]. Group 2: Research and Publications - Multiple abstracts and posters will feature NGAL research from academic clinicians globally, with a notable publication discussing NGAL's role in predicting kidney support therapy duration in critically ill children [3]. - The research on NGAL is significant as there is currently no standard of care in this area, indicating potential future diagnostic applications [3]. Group 3: Company Information - BioPorto has facilities in Copenhagen and Boston, and its shares are listed on the Nasdaq Copenhagen stock exchange [6].

July 28, 2025 News Release BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants. Laboratory medicine continues to focus on kidney diagnostics. ADLM education for members includes an online 2024 event recording which highlighted Dr. Prasad Devarajan speaking on the Use of the new Biomarker NGAL in Acute Kidney Injury. There is expected continued interest and awareness on AKI throughout 2025 and 2026 due to th ...